VMP 36047011000001105

Search dm+d | Analyse prescribing for this drug | See prices paid for this drug and its variants

Name Insulin aspart 100units/ml solution for injection 10ml vials
BNF code 0601011A0AAAAAA
Virtual Therapeutic Moiety Insulin aspart
Date identifier became valid 29 Oct 2018
Previous product identifier 325076004
Basis of preferred name rINN - Recommended International Non-proprietary
Date of name applicability 11 Oct 2004
Previous name Insulin aspart (recombinant human insulin analogue) 100units/ml solution for injection 10ml vials
Basis of previous name rINN - Recommended International Non-proprietary
Reason for name change Other
Prescribing status Caution - AMP level prescribing advised
Sugar free
Gluten free
Preservative free
CFC free
Dose form Discrete
Unit dose form size 10.000
Unit dose form units ml
Unit dose unit of measure vial
Virtual Product Ingredient
Ingredient Insulin aspart
Basis of pharmaceutical strength Based on Ingredient Substance
Strength value numerator 100.000
Strength value numerator unit unit
Strength value denominator 1.000
Strength value denominator unit ml
Ontology Drug Form & Route
Form & Route solutioninfusion.subcutaneous
Ontology Drug Form & Route
Form & Route solutioninjection.intravenous
Ontology Drug Form & Route
Form & Route solutioninjection.subcutaneous
Dose Form
Formulation Solution for injection
Drug Route
Route Intravenous
Drug Route
Route Subcutaneous
Controlled Drug Prescribing Information
Controlled Drug category No Controlled Drug Status
Actual Medicinal Products
Fiasp 100units/ml solution for injection 10ml vials (Novo Nordisk Ltd)
NovoRapid 100units/ml solution for injection 10ml vials (Novo Nordisk Ltd)
NovoRapid 100units/ml solution for injection 10ml vials (Sigma Pharmaceuticals Plc)
Trurapi 100units/ml solution for injection 10ml vials (Sanofi)
Virtual Medicinal Product Packs
Insulin aspart 100units/ml solution for injection 10ml vials 1 vial

dm+d data retrieved from TRUD: release NHSBSA_5.2.0_20240520000001, imported on 20th May 2024 at 05:03:18.

Feedback